The goal of this clinical trial is to compare the safety and effectiveness of Elranatamab versus commonly used combination regimens in participants with relapsed/refractory multiple myeloma.
This trial is currently open and accepting patients.
Participants will be randomly assigned into either the experimental group (receiving elranatamab) or the comparator group (receiving one of three commonly used combination treatment regimens that will be selected by the study doctor). This study is open-label, which means that both researchers and participants will know which groups the participants have been placed in, and which treatments they will be receiving. Participants may continue to receive treatment as long as they don’t experience unacceptable side effects and their myeloma doesn’t get worse.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Additional eligibility criteria apply and can be explained by the study doctor.
Phase 3
Enrollment: 492 patients (estimated)
View MoreRead the latest news and updates on this trial.
View all clinical trial locations sorted by state.
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
Learn more about how we work with trial sponsors